Axsome sees cash runway sufficient to reach cash flow positivity
AXSM•Axsome Therapeutics expects its cash runway to support reaching cash-flow positivity under its current operating plan. Third-quarter 2026 net product revenue rose 52% year over year to $259.7 million, exceeding a $1 billion annualized run rate.
1. Revenue and cash runway
Axsome Therapeutics expects its cash runway to support reaching cash-flow positivity under its current operating plan. Third-quarter 2026 net product revenue rose 52% year over year to $259.7 million, exceeding a $1 billion annualized run rate.
2. Product sales potential
The company cited peak sales potential exceeding $8 billion for Auvelity in major depressive disorder. It estimated peak sales potential of $300 million to $500 million for Sunosi and $500 million to $1 billion for Symbravo.
